Description
Jakavi 5mg contains the active ingredient ruxolitinib and belongs to a class of medications called JAK inhibitors. It is primarily used to treat certain bone marrow and blood-related disorders, including intermediate-to-high-risk myelofibrosis, polycythemia vera, and graft-versus-host disease, by blocking specific enzymes that promote abnormal cell growth and inflammation. [1, 2, 3]
Key Details
- Active Substance: Ruxolitinib (as phosphate) [1]
- Primary Indications:
- Myelofibrosis: Reduces spleen size and alleviates debilitating symptoms such as fatigue, night sweats, and bone pain.
- Polycythemia Vera: Manages the condition in patients who are resistant to or cannot tolerate hydroxyurea.
- Graft-versus-Host Disease (GvHD): Treats both acute and chronic GvHD in adults and children when previous treatments (like corticosteroids) have failed. [1, 2, 3, 4, 5]
Reviews
There are no reviews yet.